evocatal invests in high-throughput technology and multiplies its screening capacity
03-Dec-2010
- Germany
The evocatal GmbH puts its new high-throughput screening lab located in the Life-Science Centre Duesseldorf into operation. The company multiplies its capacity for the development of new enzymes with this step. Accordingly the time-to-market period is significantly shortened through automization.
Together with the scientific advisory board and evocatal’s 17-strong team CSO Dr. Christian Leggewie opens up the newly established high-throughput laboratory in the Life Science Centre Duesseldorf.
The investment enables evocatal to reduce development periods for customized biocatalysts immensely. This applies for projects with cooperation partners as well as for supplying efficient enzymes for the internal production of fine chemicals.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Millipore Obtains Patent Rights for Sequencing Reaction Clean-up from Japanese Research Institute
Society for Clinical Data Management (SCDM) - Brüssel, Belgium
New gene transfer strategy shows promise for limb girdle and other muscular dystrophies
Computer simulation of protein malfunction related to Alzheimer's disease
AI tailors artificial DNA for future drug development - DNA molecules made-to-order: “What otherwise takes years is now shortened to weeks or days”
Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”
Bacterial soundtracks revealed by graphene membrane - Have you ever wondered if bacteria make distinctive sounds?
